Natural products-based antiangiogenic agents: New frontiers in cancer therapy

Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides a comprehensive overview of natural product-based antiangiogenic therapies, focusing on molecular mechanisms and therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various natural compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega-3 fatty acids, polysaccharides, proteins, and carotenoids, were investigated for their antiangiogenic properties. Challenges such as dose standardization, routes of administration, and potential side effects remain. Further studies, including in-depth animal models and human epidemiological studies, must elucidate clinical efficacy and safety. Synergistic effects with current antiangiogenic therapies, such as bevacizumab and tyrosine kinase inhibitors, should be explored. Additionally, the potential hormone-dependent effects of compounds like genistein highlight the need for safety evaluation. In conclusion, natural products hold promise as adjunctive therapies to conventional antineoplastic drugs in modulating angiogenesis in cancer. However, robust clinical trials are needed to validate preclinical findings and ensure safety and efficacy. Natural products, in synergy with classic antineoplastic drugs, enhance cancer therapy by targeting multiple signaling pathways involved in tumor angiogenesis. This combined approach reduces cancer cell proliferation and migration while promoting apoptosis. Natural products are efficiently absorbed through the gastrointestinal tract, exhibit minimal side effects, and may mitigate the toxicity of conventional chemotherapy. Together, they improve the therapeutic efficacy of treatment and contribute to an enhanced quality of life for patients. image